Kwality Pharmaceuticals
add_icon

Kwality Pharmaceuticals

1,362.00
+214.50
(18.69%)
Market Cap
1,413.28 Cr
PE Ratio
24.28
Volume
2,51,784.00
Day High - Low
1,377.00 - 1,150.00
52W High-Low
1,235.00 - 596.05
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,413.28 Cr
EPS
38.36
PE Ratio
24.28
PB Ratio
4.12
Book Value
280.56
EBITDA
82.30
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
15.17
Debt to Equity
0.43
Forecast For
Actual

Company News

View All News
Caret
positive
Kwality Pharmaceuticals reported impressive Q3 FY26 results with revenue growing 46.2% YoY to INR 123.4 crore and PAT surging 87.8% to INR 16 crore, driven by expansion in regulated markets and capacity scaling.
neutral
Kwalite Pharmaceuticals Limited has scheduled its board meeting for February 12, 2026, to consider and approve Q3FY26 unaudited financial results. Trading window remains closed until 48 hours post-declaration.
positive
Kwality Pharmaceuticals Ltd appoints CA Bhavesh Mahajan as Additional Independent Director for 5-year term from January 28, 2026 to January 27, 2031, subject to shareholder approval.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,714.90
#1 4,11,461.95
37.47
#1 54,729.00
9.71
#1 10,980
16.07
57.52
6,185.00
1,64,192.32
69.33
9,712.00
18.67
2,191
-1.02
49.47
4,077.20
1,37,990.97
64.16
11,539.40
6.99
1,911
30.46
59.30
1,330.00
1,07,433.65
24.05
28,409.50
7.12
5,291
-57.18
35.19
1,274.90
1,06,407.02
19.20
33,741.20
16.73
5,725
-15.28
60.28
2,211.10
1,01,002.78
23.22
22,909.50
13.74
3,306
#1 72.75
59.86
920.95
92,669.12
#1 17.98
23,511.00
18.55
4,615
-0.32
56.49
2,079.00
85,822.17
47.77
12,744.20
#1 20.90
2,007
7.65
44.09
5,870.50
70,190.63
29.21
13,458.30
3.70
2,216
10.98
61.43
1,157.90
67,251.02
19.10
32,345.60
9.43
3,484
7.59
47.09
Growth Rate
Revenue Growth
20.42 %
Net Income Growth
68.64 %
Cash Flow Change
22.66 %
ROE
42.98 %
ROCE
34.64 %
EBITDA Margin (Avg.)
0.32 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
121
184
89
66
71
57
57
70
68
70
79
93
80
90
85
117
112
112
124
Expenses
73
100
64
48
52
40
41
74
54
54
61
78
63
70
67
90
87
86
94
EBITDA
49
84
25
18
18
17
16
-4
14
16
17
14
18
20
18
27
25
26
30
Operating Profit %
40 %
45 %
28 %
25 %
26 %
28 %
27 %
-7 %
20 %
22 %
21 %
15 %
22 %
22 %
21 %
22 %
22 %
23 %
24 %
Depreciation
2
3
3
3
3
4
4
4
5
5
5
5
4
5
5
5
5
5
5
Interest
1
1
1
1
1
1
2
2
2
2
3
3
3
3
2
3
3
3
3
Profit Before Tax
46
80
22
14
14
12
10
-10
7
8
10
6
11
13
11
19
17
19
22
Tax
11
21
6
4
4
2
3
-2
2
2
2
2
3
4
3
5
5
4
6
Net Profit
34
60
16
11
11
9
7
-7
5
6
8
4
8
9
9
15
12
14
16
EPS in ₹
32.96
57.33
15.20
9.97
9.99
8.82
6.82
-7.23
5.10
5.99
7.39
4.08
8.04
8.15
8.21
13.95
11.49
13.60
15.42

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
37
51
71
96
105
133
166
341
354
394
447
Fixed Assets
13
13
17
20
29
43
57
92
121
139
146
Current Assets
25
38
53
75
75
89
106
228
207
243
284
Capital Work in Progress
0
0
0
0
0
0
3
12
14
0
0
Investments
1
2
3
5
4
3
4
0
0
0
0
Other Assets
24
37
51
71
72
87
102
237
219
255
302
Total Liabilities
37
51
71
96
105
133
166
341
354
394
447
Current Liabilities
17
27
42
62
61
68
78
140
126
152
170
Non Current Liabilities
1
3
4
6
8
20
28
21
29
20
15
Total Equity
19
21
25
29
36
45
60
180
199
223
262
Reserve & Surplus
15
17
20
19
27
36
51
171
190
214
254
Share Capital
4
5
5
10
10
10
10
10
10
10
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
1
0
2
-1
-0
0
4
3
-6
-1
10
Investing Activities
-1
-3
-7
-6
-12
-18
-23
-63
-48
-26
-29
Operating Activities
1
-3
4
-1
14
6
27
61
41
43
53
Financing Activities
1
6
5
5
-2
12
1
6
1
-17
-14

Share Holding

% Holding
Mar 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
54.13 %
54.24 %
54.24 %
54.43 %
54.45 %
54.45 %
54.45 %
54.74 %
54.74 %
54.77 %
54.77 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
54.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.50 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.02 %
0.03 %
0.32 %
0.33 %
0.33 %
0.33 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
23.18 %
25.38 %
25.91 %
26.29 %
26.54 %
26.25 %
25.92 %
26.27 %
29.29 %
31.64 %
32.95 %
31.70 %
31.78 %
32.78 %
33.25 %
33.39 %
33.32 %
33.68 %
33.02 %
Others
22.69 %
20.38 %
19.84 %
19.28 %
19.01 %
19.30 %
19.63 %
18.99 %
15.96 %
13.58 %
12.27 %
13.47 %
13.40 %
12.38 %
11.90 %
11.47 %
11.52 %
11.16 %
11.32 %
No of Share Holders
148
168
379
581
1,049
4,198
5,376
6,211
6,943
6,291
5,786
5,695
5,273
7,487
8,947
9,420
10,115
11,595
10,709

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 1.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
12 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2026 1,058.00 1,147.50
12 Oct 2017 BONUS Bonus
1:1
11 Oct 2017 0.00 0.00
24 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
24 Sept 2024 783.50 808.10
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 818.30 812.35
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 892.20 870.20
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2025 719.45 809.00
11 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Aug 2025 1,124.45 1,132.65
09 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Sept 2025 1,069.05 946.35
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 898.20 881.15

Announcements

Investor Presentation Of Financial Results For The Quarter And Nine Months Ended December 31 20257 hrs ago
Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 31-12-20257 hrs ago
Board Meeting Outcome for Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 20257 hrs ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
Announcement under Regulation 30 (LODR)-Change in Management8 days ago
Announcement under Regulation 30 (LODR)-Change in Management10 days ago
Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On 31St December 2025.10 days ago
Board Meeting Outcome for Appointment Of Mr. Bhavesh Mahajan (DIN: 09614108) As Additional Independent Director Of The CompanyJan 28, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 28, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2026
Board Meeting Outcome for Appointment Of Mr. Preetmohinder Singh Bedi (DIN: 11452004) As Additional Independent Director Of The CompanyJan 01, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 01, 2026
Closure of Trading WindowDec 26, 2025
Intimation Of Change In Name Of Managing Director Of The CompanyDec 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2025
Unaudited Financial Results For The Quarter And Half Year Ended 30-09-2025Nov 13, 2025
Board Meeting Outcome for To Consider And Approve The Financial Results For The Quarter And Half Year Ended 30-09-2025Nov 13, 2025
Successful Completion Of The EU-GMP Audit At Its Amritsar General And Beta-Lactam UnitsNov 06, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On 30Th September 2025.Nov 05, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 11, 2025
Closure of Trading WindowSep 27, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Regularization And Reappointment Of Directors At AGMSep 10, 2025
Appointment Of Secretarial Auditors Of The CompanySep 09, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 22, 2025
Kwality Pharma Receives Product Registration For Bleomycin 15 IU In Mexico For Sale And Distribution.Aug 18, 2025
Notice Of 42Nd AGM Of The Company Scheduled To Be Held On 09Th September 2025Aug 16, 2025
Reg. 34 (1) Annual Report.Aug 16, 2025
Intimation Of Book ClosureAug 16, 2025
42Nd Annual General Meeting (AGM) Of The Shareholders Of The Company Will Be Held On Tuesday The 09Th September 2025 At 12:00 Noon Through Video Conference (VC) / Other Audio Visual Means (OAVM)Aug 16, 2025
Board Meeting Outcome for Board Meeting Outcome For Intimation Of AGMAug 16, 2025
Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Board Meeting Outcome for Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended June 30 2025Aug 11, 2025
Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On 30Th June 2025.Aug 04, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorJul 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 26, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
Board Meeting Outcome for Audited Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 19, 2025
Conclusion Of Regulatory Audit For ZimbabweMay 07, 2025
Board Meeting Intimation for Considering The Standalone & Consolidated Audited Financial Results For The 4Th Quarter And Financial Year Ended On 31St March 2025May 06, 2025
Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November 2018- Fund Raising By Issuance Of Debt Securities By Large CorporateApr 30, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Closure of Trading WindowMar 26, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.04%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
56.43
ATR(14)
Less Volatile
59.65
STOCH(9,6)
Neutral
68.88
STOCH RSI(14)
Neutral
57.80
MACD(12,26)
Bullish
3.47
ADX(14)
Weak Trend
16.63
UO(9)
Bearish
53.20
ROC(12)
Uptrend And Accelerating
8.94
WillR(14)
Neutral
-38.75